Phase III trials testing nivolumab upon chemotherapy failure showed a correlation between PD-L1 expression and clinical benefit in lung adenocarcinoma, whereas in squamous NSCLC, it was neither prognostic nor predictive of response [41,42]. Here, CD274 is linked to lung adenocarcinoma.